Afucosylated humanized monoclonal antibody against IL-5 receptor alpha (IL-5Rα) that blocks IL-5 signaling and engages Fcγ receptors to drive enhanced antibody-dependent cellular cytotoxicity, inducing apoptosis and depletion of IL-5Rα-expressing eosinophils (and basophils) to reduce eosinophilic inflammation.
YES
DIRECT
Benralizumab binds IL-5Rα on eosinophils/basophils and its afucosylated Fc engages FcγRIIIa on NK cells, triggering potent ADCC that induces apoptosis and depletion of IL-5Rα-expressing cells.
Afucosylated humanized monoclonal antibody against IL-5 receptor alpha (IL-5Rα) that blocks IL-5 signaling and engages Fcγ receptors to drive enhanced antibody-dependent cellular cytotoxicity, inducing apoptosis and depletion of IL-5Rα-expressing eosinophils (and basophils) to reduce eosinophilic inflammation.
NO
INDIRECT
Benralizumab binds IL-5Rα on eosinophils; its afucosylated Fc engages FcγRIIIa (CD16a) on NK cells to trigger ADCC, killing IL-5Rα+ eosinophils. CD16a-expressing cells act as effectors, not targets.
Celltrion’s proposed biosimilar of ocrelizumab, a humanized IgG1 monoclonal antibody that binds CD20 on pre‑B to mature B lymphocytes, depleting them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and inducing apoptosis; plasma cells are spared. Administered intravenously.
Humanized IgG1 monoclonal antibody (biosimilar to ocrelizumab) that binds CD20 on pre-B to mature B lymphocytes and depletes them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, with induction of apoptosis; plasma cells (CD20-negative) are spared. This B-cell depletion reduces antigen presentation, costimulation, and proinflammatory cytokines, modulating CNS autoimmunity in multiple sclerosis.
YES
DIRECT
Anti-CD20 IgG1 binds CD20 on B cells and induces killing via antibody-dependent cellular cytotoxicity (FcγR-mediated) and complement-dependent cytotoxicity; can also trigger apoptosis.
US-licensed ocrelizumab, a humanized IgG1 anti-CD20 monoclonal antibody that depletes CD20+ B cells via antibody-dependent and complement-dependent cytotoxicity and induces apoptosis; plasma cells are spared. Administered intravenously.
Humanized IgG1 anti‑CD20 monoclonal antibody that binds CD20 on pre‑B to mature B lymphocytes and depletes them via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and apoptosis; plasma cells (CD20−) are spared, reducing B‑cell–mediated immune activity.
YES
DIRECT
Anti-CD20 antibody binds CD20 on B cells and triggers killing via antibody-dependent cellular cytotoxicity (effector cells like NK cells), complement-dependent cytotoxicity, and induction of apoptosis.
EU-licensed ocrelizumab, a humanized IgG1 anti-CD20 monoclonal antibody that depletes CD20+ B cells via antibody-dependent and complement-dependent cytotoxicity and induces apoptosis; plasma cells are spared. Administered intravenously.
Humanized IgG1 anti‑CD20 monoclonal antibody that binds CD20 on pre‑B to mature B cells, depleting them via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and apoptosis; plasma cells (CD20−) are spared, reducing antigen presentation and pro‑inflammatory cytokine signaling.
YES
DIRECT
Anti-CD20 mAb binds CD20 on B cells and triggers killing via Fc-mediated ADCC by NK/macrophages, complement-dependent cytotoxicity (CDC), and apoptosis of the bound cells.